Skip to content

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00332345
Enrollment
73
Registered
2006-06-01
Start date
1999-07-31
Completion date
1999-08-31
Last updated
2011-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Hypertension

Brief summary

The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed Combination in patients with glaucoma or ocular hypertension

Interventions

Sponsors

Allergan
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of glaucoma or ocular hypertension in both eyes * Patient requires IOP-lowering in both eyes

Exclusion criteria

* Uncontrolled medical conditions * Contraindication to beta-andrenoceptor antagonist or brimonidine therapy

Design outcomes

Primary

MeasureTime frame
IOP

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026